Home » Stocks » AYTU

Aytu BioScience, Inc. (AYTU)

Stock Price: $7.44 USD 0.05 (0.68%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $7.60 +0.16 (2.15%) Jan 15, 7:58 PM
Market Cap 128.31M
Revenue (ttm) 39.71M
Net Income (ttm) -13.00M
Shares Out 12.16M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE 10.70
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $7.44
Previous Close $7.39
Change ($) 0.05
Change (%) 0.68%
Day's Open 7.48
Day's Range 7.17 - 7.60
Day's Volume 523,723
52-Week Range 3.48 - 20.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 weeks ago

Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has sign...

Benzinga - 2 weeks ago

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...

Other stocks mentioned: KNTE, MYOV, OSMT
Accesswire - 2 weeks ago

First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu...

PRNewsWire - 1 month ago

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the...

Other stocks mentioned: NEOS
Benzinga - 1 month ago

The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) ...

Other stocks mentioned: GILD
Seeking Alpha - 2 months ago

Aytu reported Q4 results in October that beat estimates across the board with revenue of $14.86 million, surpassing the $11.24 million revenue analysts were projecting. A careful review of the...

Benzinga - 3 months ago

Shares of Aytu BioScience (NASDAQ:AYTU) fell 6.77% after the company reported Q4 results. Quarterly Results Earnings per share rose 98.46% over the past year to ($0.02), which beat the estimat...

Benzinga - 3 months ago

Aytu BioScience (NASDAQ: AYTU) releases its next round of earnings this Tuesday, October 06. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

Benzinga - 3 months ago

On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report.

Zacks Investment Research - 5 months ago

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Zacks Investment Research - 5 months ago

Aytu Bioscience, Inc. (AYTU) closed at $1.39 in the latest trading session, marking a +1.46% move from the prior day.

Zacks Investment Research - 6 months ago

Is (AYTU) Outperforming Other Medical Stocks This Year?

24/7 Wall Street - 6 months ago

Some small companies are destined to be small forever. Others can grow into massive companies over time.

Zacks Investment Research - 6 months ago

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 6 months ago

Aytu BioScience: The Next Arbor Pharmaceuticals?

Zacks Investment Research - 7 months ago

Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

24/7 Wall Street - 7 months ago

Aytu BioScience Inc. (NASDAQ: AYTU) stock has been a huge beneficiary of the coronavirus pandemic.

24/7 Wall Street - 7 months ago

Aytu BioScience, Inc. (NASDAQ: AYTU) has been one of the biggest winners from COVID-19.

Zacks Investment Research - 7 months ago

Is (AYTU) Outperforming Other Medical Stocks This Year?

24/7 Wall Street - 7 months ago

Aytu BioScience, Inc. (NASDAQ: AYTU) is a specialty pharmaceutical company focused on commercializing novel products related to low testosterone, upper respiratory problems, insomnia, and more.

Seeking Alpha - 8 months ago

Aytu BioScience, Inc.'s (AYTU) CEO Joshua Disbrow on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020.

24/7 Wall Street - 8 months ago

Aytu BioScience Inc. (NASDAQ: AYTU) has been a stock market darling since it broke onto the COVID-19 testing scene.

Zacks Investment Research - 8 months ago

Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.

Zacks Investment Research - 8 months ago

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 8 months ago

Aytu Bioscience, Inc. (AYTU) closed at $1.64 in the latest trading session, marking a +1.23% move from the prior day.

24/7 Wall Street - 8 months ago

On March 9, pharmaceutical company Aytu Bioscience Inc. (NASDAQ: AYTU) posted a 52-week low of $0.34 per share.

Zacks Investment Research - 8 months ago

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.

24/7 Wall Street - 8 months ago

Aytu BioScience Inc. (NASDAQ: AYTU) shares made an incredible gain to start the week following the firm’s announcement in regards to a coronavirus treatment.

Seeking Alpha - 8 months ago

Aytu BioScience's (AYTU) CEO Josh Disbrow on COVID-19 Initiatives - Update Call

Zacks Investment Research - 8 months ago

Is (AYTU) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 8 months ago

Aytu BioScience: A Corona-Portunist With 40%+ Downside

24/7 Wall Street - 9 months ago

Aytu BioScience Inc. (NASDAQ: AYTU) has been one of the biggest winners in the fight against the novel coronavirus.

Zacks Investment Research - 9 months ago

Aytu Bioscience, Inc. (AYTU) closed at $1.55 in the latest trading session, marking a -1.27% move from the prior day.

Zacks Investment Research - 9 months ago

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 9 months ago

Aytu Bioscience, Inc. (AYTU) closed at $1.52 in the latest trading session, marking a -1.3% move from the prior day.

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for April 3rd

Other stocks mentioned: CTMX, DHT, ECOR
Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for April 2nd

Other stocks mentioned: DHT, EURN, NOVN
24/7 Wall Street - 9 months ago

In less than 24 hours, the stock price of Aytu Bioscience Inc. (NASDAQ: AYTU) set both a 52-week high and a 52-week low earlier this month.

Zacks Investment Research - 9 months ago

Aytu BioScience (AYTU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Investment Research - 9 months ago

Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

Zacks Investment Research - 9 months ago

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Other stocks mentioned: ARKG, BBH, CNCR, CNTG, CODX, FTSV, IBB, IDNA, VIR
Zacks Investment Research - 9 months ago

Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.

Other stocks mentioned: CODX, QDEL
Benzinga - 9 months ago

Shares of Aytu Bioscience Inc (NASDAQ: AYTU), which announced earlier this month a deal to distribute a COVID-19 test, were rallying Monday after the company announced FDA approval for distrib...

24/7 Wall Street - 9 months ago

Aytu BioScience Inc. (NASDAQ: AYTU) has made a splash in the market since it got into the coronavirus test business.

24/7 Wall Street - 10 months ago

On March 10, specialty pharmaceutical maker Aytu Bioscience Inc. (NASDAQ: AYTU) announced that it had licensed North American rights to distribute a coronavirus test kit div.connatix{margin: 1...

24/7 Wall Street - 10 months ago

Markets looked like they would be crushed yet again on Monday despite the emergency Federal Reserve rate cut announced on Sunday.

Other stocks mentioned: ALT, CLX, CODX, DGX, GILD, INO, LAKE, NNVC, NVAX, ZM
Benzinga - 10 months ago

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: CANF, ENTA, LJPC, LLY, OPK, RHHBY
24/7 Wall Street - 10 months ago

Markets were crushed again on Thursday after President Trump announced a travel ban to Europe on Wednesday night.

Other stocks mentioned: ALT, CLX, CODX, DGX, GILD, INO, LAKE, NNVC, NVAX, ZM
Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Aytu BioScience, Inc. (AYTU).

About AYTU

Aytu BioScience, a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for th... [Read more...]

Industry
Biotechnology
CEO
Joshua R. Disbrow
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
AYTU
Full Company Profile

Financial Performance

In 2020, AYTU's revenue was $27.63 million, an increase of 277.47% compared to the previous year's $7.32 million. Losses were -$13.62 million, -49.80% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for AYTU stock is "Buy." The 12-month stock price forecast is 23.60, which is an increase of 217.20% from the latest price.

Price Target
$23.60
(217.20% upside)
Analyst Consensus: Buy